BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22891763)

  • 1. Fas-associated phosphatase 1 mediates Fas resistance in myeloid progenitor cells expressing the Bcr-abl oncogene.
    Huang W; Bei L; Eklund EA
    Leuk Lymphoma; 2013 Mar; 54(3):619-30. PubMed ID: 22891763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interferon consensus sequence-binding protein (ICSBP/IRF8) represses PTPN13 gene transcription in differentiating myeloid cells.
    Huang W; Zhu C; Wang H; Horvath E; Eklund EA
    J Biol Chem; 2008 Mar; 283(12):7921-35. PubMed ID: 18195016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas-associated phosphatase 1 (Fap1) influences βcatenin activity in myeloid progenitor cells expressing the Bcr-abl oncogene.
    Huang W; Bei L; Eklund EA
    J Biol Chem; 2013 May; 288(18):12766-76. PubMed ID: 23519466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription.
    Huang W; Zhou W; Saberwal G; Konieczna I; Horvath E; Katsoulidis E; Platanias LC; Eklund EA
    Mol Cell Biol; 2010 Oct; 30(19):4575-94. PubMed ID: 20679491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
    Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
    Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells.
    Tamura T; Kong HJ; Tunyaplin C; Tsujimura H; Calame K; Ozato K
    Blood; 2003 Dec; 102(13):4547-54. PubMed ID: 12933588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The leukemia-associated fusion protein Tel-platelet-derived growth factor receptor β (Tel-PdgfRβ) inhibits transcriptional repression of PTPN13 gene by interferon consensus sequence binding protein (Icsbp).
    Huang W; Hu L; Bei L; Hjort E; Eklund EA
    J Biol Chem; 2012 Mar; 287(11):8110-25. PubMed ID: 22262849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Interferon Consensus Sequence Binding Protein (Icsbp/Irf8) Is Required for Termination of Emergency Granulopoiesis.
    Hu L; Huang W; Hjort EE; Bei L; Platanias LC; Eklund EA
    J Biol Chem; 2016 Feb; 291(8):4107-20. PubMed ID: 26683374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.
    Hjort EE; Huang W; Hu L; Eklund EA
    Oncotarget; 2016 Nov; 7(47):77635-77650. PubMed ID: 27769062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.
    Burchert A; Cai D; Hofbauer LC; Samuelsson MK; Slater EP; Duyster J; Ritter M; Hochhaus A; Müller R; Eilers M; Schmidt M; Neubauer A
    Blood; 2004 May; 103(9):3480-9. PubMed ID: 14656881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interferon consensus sequence binding protein (ICSBP/IRF8) activates transcription of the FANCF gene during myeloid differentiation.
    Saberwal G; Horvath E; Hu L; Zhu C; Hjort E; Eklund EA
    J Biol Chem; 2009 Nov; 284(48):33242-54. PubMed ID: 19801548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morgana acts as an oncosuppressor in chronic myeloid leukemia.
    Di Savino A; Panuzzo C; Rocca S; Familiari U; Piazza R; Crivellaro S; Carrà G; Ferretti R; Fusella F; Giugliano E; Camporeale A; Franco I; Miniscalco B; Cutrin JC; Turco E; Silengo L; Hirsch E; Rege-Cambrin G; Gambacorti-Passerini C; Pandolfi PP; Papotti M; Saglio G; Tarone G; Morotti A; Brancaccio M
    Blood; 2015 Apr; 125(14):2245-53. PubMed ID: 25678499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
    Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
    Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
    Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
    Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL.
    Gora-Tybor J; Deininger MW; Goldman JM; Melo JV
    Br J Haematol; 1998 Dec; 103(3):716-20. PubMed ID: 9858222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
    Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
    Cancer Lett; 2015 Jan; 356(2 Pt B):597-605. PubMed ID: 25305453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
    Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.